Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars

Juan V. Esplugues; Bruno Flamion; Lluis Puig

doi:10.1016/j.nhtm.2016.10.002

Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars

Juan V. Esplugues, Bruno Flamion, Lluis Puig

Unite de recherche en physiologie moleculaire

Résultats de recherche: Contribution à un journal/une revue › Commentaire/débat › Revue par des pairs

Résumé

The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.

langue originale	Anglais
Pages (de - à)	161
Nombre de pages	1
journal	New Horizons in Translational Medicine
Volume	3
Numéro de publication	3-4
Les DOIs	https://doi.org/10.1016/j.nhtm.2016.10.002
Etat de la publication	Publié - 1 déc. 2016

Accès au document

10.1016/j.nhtm.2016.10.002

Autres fichiers et liens

Link to publication in Scopus

Contient cette citation

@article{22d230533b914af5a197ac5422a7cbb4,

title = "Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars",

abstract = "The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.",

author = "Esplugues, {Juan V.} and Bruno Flamion and Lluis Puig",

year = "2016",

month = dec,

day = "1",

doi = "10.1016/j.nhtm.2016.10.002",

language = "English",

volume = "3",

pages = "161",

journal = "New Horizons in Translational Medicine",

issn = "2307-5023",

publisher = "Elsevier",

number = "3-4",

}

TY - JOUR

T1 - Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars

AU - Esplugues, Juan V.

AU - Flamion, Bruno

AU - Puig, Lluis

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.

AB - The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.

UR - http://www.scopus.com/inward/record.url?scp=84994579983&partnerID=8YFLogxK

U2 - 10.1016/j.nhtm.2016.10.002

DO - 10.1016/j.nhtm.2016.10.002

M3 - Comment/debate

AN - SCOPUS:84994579983

SN - 2307-5023

VL - 3

SP - 161

JO - New Horizons in Translational Medicine

JF - New Horizons in Translational Medicine

IS - 3-4

ER -

Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars

Résumé

Accès au document

Autres fichiers et liens

Empreinte digitale

Contient cette citation